Released Nov 12, 2024, after the close
10-Q filed Nov 12, 2024, 43 days after period end · 0000950170-24-125317
Q3 2024 · 10-Q
Revenue$3.07M$3.07M +58.1% vs Q3 2023−54.6% vs Q2 2024
Net Income-$47.68M-$47.68M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.40-$0.40 N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$52,377,000N/M
Operating Cash Flowderived-$29,419,000N/M
Free Cash Flowderived-$29,914,000N/M
Margins · derived
Operating margin-1703.9%+933.9 pt vs Q3 2023
Net margin-1551.0%+772.6 pt vs Q3 2023
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $3.07M | $1.94M | $14.98M | $14.23M |
| Net Income | -$47.68M | -$45.17M | -$83.56M | -$43.31M |
| EPS Diluted | -$0.40 | -$0.46 | -$0.86 | -$0.45 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR